Cellular localization, expression, and structure of the nuclear dot protein 52

Area of Science:

• Cell biology
• Molecular biology
• Immunology

Background:

• Nuclear dots (NDs) containing PML and Sp100 proteins are implicated in acute promyelocytic leukemia, viral infections, and autoimmunity in primary biliary cirrhosis (PBC).
• Interferons (IFN) strongly enhance PML and Sp100 gene expression.
• Previous studies suggested nuclear dot protein 52 (NDP52) localizes to NDs based on a specific monoclonal antibody (mAb C8A2).

Purpose of the Study:

• To investigate the cellular localization, expression, and structure of NDP52 in detail.
• To clarify NDP52's relationship with NDs, PML, Sp100, and its autoantigenicity in PBC.

Main Methods:

• Immunostaining using NDP52-specific sera and mAb C8A2.
• Expression vector transfections.
• Subcellular fractionation.
• Quantitative analysis of mRNA and protein levels.
• Dimerization assays.
• Screening of patient sera for autoantibodies.

Main Results:

• NDP52 primarily shows cytoplasmic staining, with no detectable ND localization, even after IFN treatment.
• NDP52 mRNA and protein levels are only marginally affected by IFN-gamma and not by IFN-beta.
• NDP52 forms homodimers but does not heterodimerize with Sp100 or PML.
• No autoantibodies against NDP52 were found in 93 PBC patient sera.
• mAb C8A2 recognizes both NDP52 and a conformation-dependent epitope on Sp100.

Conclusions:

• NDP52 localizes mainly in the cytoplasm and is associated with the nucleus, but not with NDs.
• NDP52 exhibits homodimerization capabilities but does not heterodimerize with Sp100 or PML.
• NDP52 is not autoantigenic in PBC patients.
• NDP52 expression and localization are largely unaffected by type I and II interferons, contrasting with PML and Sp100.